Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

被引：0
|
作者：
Bharathi, Vanthana [1 ]
Bataller, Alex [2 ]
Bazinet, Alexandre [1 ]
Borthakur, Gautam [3 ]
Jabbour, Elias [1 ]
Daver, Naval [4 ]
Short, Nicholas J. [1 ]
Takahashi, Koichi [1 ]
Issa, Ghayas C. [1 ]
Dinardo, Courtney D. [1 ]
Pemmaraju, Naveen [1 ]
Jain, Nitin [1 ]
Montalban-Bravo, Guillermo [1 ]
Wierda, William G. [2 ]
Ravandi, Farhad [1 ]
Kantarjian, Hagop M. [1 ]
Kadia, Tapan M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Sect Mol Hematol & Therapy, Houston, TX USA
[4] MD Anderson Canc Ctr, Houston, TX USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-209157
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4272 / 4274
页数：3
相关论文
共 50 条
  • [31] CPX-351 in Patients with Newly Diagnosed Post Myeloproliferative Neoplasms Acute Myeloid Leukemia
    Garciaz, Sylvain
    Belhabri, Amine
    Guieze, Romain
    Goursaud, Laure
    Peterlin, Pierre
    Ledoux, Marie-Pierre
    Mathilde, Hunault-Berger
    Chebrek, Safia
    Robin, Jean-Baptiste
    Pigneux, Arnaud
    Bonnet, Sarah
    Bonmati, Caroline
    Bertoli, Sarah
    Braun, Thorsten
    Chantepie, Sylvain
    Meunier, Mathieu
    Heiblig, Mael
    Cluzeau, Thomas
    Jourdan, Eric
    Villate, Alban
    Recher, Christian
    Vey, Norbert
    Rey, Jerome
    BLOOD, 2023, 142
  • [32] CPX-351 in FLT3-mutated acute myeloid leukemia
    Andrews, Claire
    Pullarkat, Vinod
    Recher, Christian
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [33] Liposomal cytarabine and daunorubicin (CPX-351) for treatment of acute myeloid leukemia
    Ronson, Aaron
    Tvito, Ariella
    Rowe, Jacob M.
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (04): : 369 - 374
  • [34] Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia
    Talati, Chetasi
    Goldberg, Aaron D.
    Desai, Pinkal
    Chan, Onyee
    Famulare, Christopher
    Komrokji, Rami S.
    Kuykendall, Andrew T.
    Fernandez, Hugo F.
    Deutsch, Yehuda E.
    Padron, Eric
    List, Alan F.
    Lancet, Jeffrey E.
    Roboz, Gail J.
    Tallman, Martin S.
    Sallman, David A.
    Sweet, Kendra L.
    BLOOD, 2018, 132
  • [35] V2 THERAPY: VENETOCLAX WITH VYXEOS (CPX-351) FOR ACUTE MYELOID LEUKEMIAS IN YOUNG PATIENTS
    Agresta, Laura
    Young, Jennifer
    Breese, Erin
    Phillips, Christine
    Burns, Karen
    Mizukawa, Benjamin
    Lee, Lynn
    Norris, Robin
    O'Brien, Maureen
    Perentesis, John
    Absalon, Michael
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S187 - S188
  • [36] A phase II study of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia: Trial in progress.
    Swaminathan, Mahesh
    Fazal, Salman
    Griffiths, Elizabeth A.
    Thompson, James E.
    Sung, Pamela Jeannette
    Green, Steven Daniel
    Li, Emily
    Said, Meriem
    Belko, Krista
    Mattice, Emmalyn
    Attwood, Kristopher
    Wang, Eunice S.
    Przespolewski, Amanda
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] Phase Ib study of CPX-351 lower-intensity therapy (LIT) plus venetoclax as first-line treatment for patients with AML who are unfit for intensive chemotherapy (IC).
    Lin, Tara L.
    Uy, Geoffrey L.
    Walter, Roland B.
    Zou, Heng
    Wang, Qi
    Faderl, Stefan
    Cheung, Ronald
    Pullarkat, Vinod A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia
    Murthy, Guru Subramanian Guru
    Saliba, Antoine N.
    Szabo, Aniko
    Harrington, Alexandra
    Abedin, Sameem
    Carlson, Karen
    Michaelis, Laura
    Runaas, Lyndsey
    Baim, Arielle
    Hinman, Alex
    Maldonado-Schmidt, Sonia
    Venkatachalam, Annapoorna
    Flatten, Karen S.
    Peterson, Kevin L.
    Schneider, Paula A.
    Litzow, Mark
    Kaufmann, Scott H.
    Atallah, Ehab
    HAEMATOLOGICA, 2024, 109 (09) : 2864 - 2872
  • [39] Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax
    Chojecki, Aleksander L.
    Arnall, Justin
    Boselli, Danielle
    Patel, Rushil
    Chiad, Zane
    DiSogra, Kristyn Y.
    Karabinos, Allison
    Chen, Tommy
    Cruz, Adilen
    Verbyla, Allison
    Ai, Jing
    Knight, Thomas G.
    Ragon, Brittany K.
    Shah, Nilay A.
    Sanikommua, Srinivasa R.
    Symanowskic, James
    Avalosa, Belinda R.
    Copelana, Edward A.
    Grunwald, Michael R.
    LEUKEMIA RESEARCH, 2022, 119
  • [40] Phase II study of the histone deacetylase inhibitor depsipeptide in patients with relapsed or refractory acute myeloid leukemia (AML).
    Odenike, OM
    Alkan, S
    Godwin, JE
    Brandt, SJ
    Sher, D
    Stiff, PJ
    Corum, L
    Vokes, EE
    Larson, R
    Stock, W
    BLOOD, 2003, 102 (11) : 241B - 242B
12345